Seres Therapeutics, Inc.
General ticker "MCRB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $117.4M (TTM average)
Seres Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -0.3%.
Estimated limits based on current volatility of 4.2%: low 7.16$, high 7.79$
Factors to consider:
- Total employees count: 103 (-55.8%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient funding, Limited pipeline diversity, Third-party risks, Regulatory and compliance, Geopolitical risks
- Current price 25.0% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.56$, 22.64$]
- 2026-12-31 to 2027-12-31 estimated range: [8.44$, 20.27$]
Financial Metrics affecting the MCRB estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of -0.03 > -0.60
- Negative: -0.75 < Inventory ratio change, % of 0
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 3.96
- Positive: -0.02 < Operating cash flow per share per price, % of 0.84
- Negative: negative Industry operating cash flow (median)
- Negative: -0.16 < Industry inventory ratio change (median), % of 0
Short-term MCRB quotes
Long-term MCRB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.79MM |
| Operating Expenses | $195.10MM | $121.31MM | $94.76MM |
| Operating Income | $-195.10MM | $-121.31MM | $-93.97MM |
| Non-Operating Income | $4.97MM | $-4.46MM | $99.67MM |
| Interest Expense | $2.47MM | $0.00MM | $0.00MM |
| R&D Expense | $117.60MM | $64.60MM | $49.06MM |
| Income(Loss) | $-190.13MM | $-125.77MM | $5.70MM |
| Other Income(Loss) | $76.41MM | $125.91MM | $0.00MM |
| Net Income(Loss)* | $-37.32MM | $0.14MM | $5.70MM |
| Stockholders Equity | $-44.86MM | $13.78MM | $44.22MM |
| Inventory | $29.65MM | $0.00MM | $0.00MM |
| Assets | $358.60MM | $139.81MM | $138.19MM |
| Operating Cash Flow | $-117.35MM | $-148.61MM | $1.12MM |
| Capital expenditure | $7.97MM | $0.38MM | $0.25MM |
| Investing Cash Flow | $10.58MM | $142.29MM | $-0.04MM |
| Financing Cash Flow | $71.70MM | $-90.37MM | $13.90MM |
| Earnings Per Share** | $-5.83 | $0.02 | $0.64 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.